IQVIA Holdings Inc. logo

IQVIA Holdings Inc. (QTS)

Market Closed
16 Jul, 06:03
XMUN XMUN
181. 18
0
0%
- Market Cap
38.04 P/E Ratio
- Div Yield
0 Volume
10.19 Eps
181.18
Previous Close
Add Transaction
Day Range
181.18 181.18
Year Range
135.16 208
Want to track QTS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

QTS closed Thursday higher at €181.18, an increase of 0% from Wednesday's close, completing a monthly increase of 7.3723% or €12.44. Over the past 12 months, QTS stock lost -5.5616%.
QTS is not paying dividends to its shareholders.
The last earnings report, released on May 04, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -2.1233%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NYSE (USD).

QTS Chart

IQV vs. PEN: Which Stock Is the Better Value Option?

IQV vs. PEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

Zacks | 4 days ago
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 week ago
Here's Why Investors Should Hold IQV Stock in Their Portfolios Now

Here's Why Investors Should Hold IQV Stock in Their Portfolios Now

IQVIA's AI tools, record R&D backlog and strong free cash flow support its outlook, but weak liquidity and no dividend remain investor concerns.

Zacks | 2 weeks ago

IQVIA Holdings Inc. (QTS) FAQ

What is the stock price today?

The current price is €181.18.

On which exchange is it traded?

IQVIA Holdings Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is QTS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has IQVIA Holdings Inc. ever had a stock split?

No, there has never been a stock split.

IQVIA Holdings Inc. Profile

Professional Services Industry
Industrials Sector
Ari Bousbib CEO
XMUN Exchange
US46266C1053 ISIN
US Country
93,000 Employees
- Last Dividend
- Last Split
9 May 2013 IPO Date

Overview

IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.

Products and Services

  • Technology & Analytics Solutions
  • This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.

  • Research & Development Solutions
  • This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.

  • Contract Sales & Medical Solutions
  • Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.

Contact Information

Address: 2400 Ellis Road
Phone: 919 998 2000